An Open Label First in Human (FIH) Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda (pembrolizumab) in Advanced or Metastatic Malignancy

Brief description of study

The purpose of the study is to look at how your body tolerates LVGN6051, how safe LVGN6051 may be, and how LVGN6051 is taken up by your body, when administered as a single agent (monotherapy) and in combination with a fixed dose of pembrolizumab. LVGN6051 is a humanized monoclonal antibody (mAb) IgG1? that specifically binds to CD137 (also known as 4-1BB or TNFRSF9), a member of the tumor necrosis factor (TNF) receptor family and a key co-stimulation receptor for effector T cells. The study drug LVGN6051 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s20-00064 Identifier: NCT04130542

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.